Targeting c-MET in Human Cancer
George F. Vande Woude, PhD
Distinguished Scientific Fellow,
Van Andel Research Institute, USA

Wnt and Met Signaling in Stem and Cancer Stem Cells
Walter Birchmeier, PhD
Professor, Research Group Leader,
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch, Germany

Structure/Function of HGF/SF and MET
Ermanno Gherardi, PhD
Principal Investigator,
Principal Investigator,
Medical Research Council(MRC) Contre,
University of Cambridge, UK

VEGF Regulates Tumor Invasion Through c-Met Signaling
Gabriele Bergers, PhD
Professor,
Department of Neurosurgery,
University of California, San Francisco, USA

c-Met Signaling and Glioma Cancer Stem Cell Phenotypes
Do-Hyun Nam, MD, PhD
Professor,
Department of Neurosurgery, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, Korea

c-Met as a Therapeutic Target in Gastric Cancer
Sun Young Rha, MD, PhD
Professor,
Division of Medical Oncology, Department of Internal Medicine
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea

Translational Research on INC280, A Selective Small Molecule inhibitor of c-Met
Yao Yao, PhD
Leader of Biomarkers
Oncology Translational Medicine
Novartis Institutes for Biomedical Research, China

The MET Oncogene: from molecular biology to the clinic
Paolo M. Comoglio, MD
Director,
Institute for cancer Research at Candiolo, Italy

Role of Clinical Trial Center for Future Medicine
Young Suk Park, MD, PhD
Professor,
Divisionof Pulmonary & Criticalcare Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, Korea

Introduction of Institute for Refractory Cancer Research
in Samsung Medical Center
Do-Hyun Nam, MD, PhD
Professor,
Department of Neurosurgery, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, Korea

c-Met and Tumor Cell Reprogramming
John J. Laterra, MD, PhD
Johns Hopkins, USA

The Development of Crizotinib for Molecularly Targeted Patient Populations
Patient Populations
James G. Christensen, PhD
Director of Precision Medicine,
Oncology Research Unit,
Pfizer La Jolla Labs, USA

Targeting HGF/c-Met Signaling with Rilotumumab (AMG 102),
a Fully Human Monoclonal Antibody Against HGF:
From Discovery Research to Phase 2 Clinical Activity
Teresa L. Burgess, PhD
Director,
Oncology Research,
Amgen, USA

LA480, a c-Met Antibody with Neutralization and Internalization Properties, Inhibits HGF-dependent and HGF-Independent c-Met Pathway Activation and Tumor Growth
Ling Liu, PhD
Research Advisor,
Biotech Discovery Research,
Lilly, USA

Prediction of Benefit from Targeted Therapies for Breast Cancer
Soonmyung Paik, MD, PhD
Director,
Division of Pathology, NSABP, USA
Director,
Samsung Cancer Research Institute, Seoul, Korea

Companion Diagnosis for MET: Guiding Therapy Decisions
Yoon-La Choi, MD, PhD
Assistant professor,
Department of pathology, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, Korea

Avatar Mice: Glioblastoma Animal Models Closely Mirror Individual Tumors
Kyeung Min Joo, MD, PhD
Assistant Professor,
Department of Anatomy,
Seoul National University College of Medicine, Seoul, Koea

Generation and functional characterization of a novel c-Met antibody
Ho Yeong Song, PhD
Assistant Professor,
Department of Anatomy,
Seoul National University College of Medicine, Seoul, Korea

Symposium Highlights
Paolo M. Comoglio, MD
Director,
Institute for cancer Research at Candiolo, Italy